Schonfeld Strategic Advisors LLC Aerie Pharmaceuticals Inc Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $1.85 Million - $4.42 Million	290,416 New	290,416 $4.39 Million
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $100,956 - $175,420	-17,900 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $17,585 - $33,391	2,505 Added 16.27%	17,900 $126,000
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $233,388 - $292,043	15,395 New	15,395 $247,000
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $285,097 - $394,121	-27,256 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $327,072 - $439,639	27,256 New	27,256 $402,000
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $2.13 Million - $4.6 Million	-180,148 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $1.63 Million - $2.32 Million	92,248 Added 104.95%	180,148 $4.35 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $1.62 Million - $2.46 Million	87,900 New	87,900 $1.69 Million
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $600,080 - $768,245	-11,801 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $573,528 - $709,240	11,801	11,801 $574,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.